Stocks · News reference

QNRX shares are trading higher after the company announced interim Phase 2/3 results showing QRX003 met the primary and key secondary endpoints with statistical significance, along with itch reduction and no serious adverse events.

Aug 28, 2026, 5:59 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 8, 2026, 12:35 PMBenzinga Newsdesk
FDA Grants Rare Pediatric Disease Designation For Quoin Pharma’s Lead Asset, QRX003, For Treatment Of Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin
QNRX
SEC EDGARAug 28, 2026, 2:31 PMSEC EDGAR
8-K filing — Quoin Pharmaceuticals, Ltd. (QNRX)
Filed: 2026-08-28 AccNo: 0001104659-26-102917 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
QNRX
BenzingaAug 28, 2026, 2:09 PMAvi Kapoor
Dow Gains 100 Points; Chicago PMI Falls In August
US stocks up, Dow gains 100 points, S&P 500 and NASDAQ also rise. Communication services up 1.1%, technology down 0.3%. Chicago Business Barometer dips.
AEHL BTAI CYAB FNGR KXIN